Interim Phase 1 Data Evaluating MOv18 IgE, an Anti-folate Receptor Alpha IgE antibody, in Cancer Patients with Advanced Solid Tumours to be Presented at the AACR Virtual Annual Meeting I
April 20, 2020
MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Folate receptor alpha most commonly overexpressed on tumour cells in ovarian cancer London,